LDR brachytherapy offers superior tumor control to single‐fraction HDR prostate brachytherapy: A prospective study-Reference-Cited by-同舟云学术

LDR brachytherapy offers superior tumor control to single‐fraction HDR prostate brachytherapy: A prospective study

Published:2023-05-07 Issue:11 Volume:83 Page:1068-1075
ISSN:0270-4137
Container-title:The Prostate
language:en
Short-container-title:The Prostate

Author:

Jimenez‐Garcia Isabel E.¹^ORCID,Sabater Sebastia¹^ORCID,Martinez‐Gutierrez Rocio²,Sanchez‐Galiano Pedro³,Berenguer‐Serrano Roberto⁴,Castro‐Larefors Susana¹^ORCID,Rey‐Lopez Irene¹,Ruiz‐Herrero Beatriz¹,Sánchez‐Prieto Ricardo⁵⁶^ORCID,Rovirosa Angeles⁷,Arenas Meritxell⁸,Gonzalez‐Suarez Herminio A.²^ORCID

Affiliation:

1. Department of Radiation Oncology Complejo Hospitalario Universitario de Albacete (CHUA) Albacete Spain

2. Department of Radiation Oncology Hospital Universitario Central de Asturias Oviedo Spain

3. Department of Radiation Physics Hospital Universitario Central de Asturias Oviedo Spain

4. Department of Radiation Physics Complejo Hospitalario Universitario de Albacete (CHUA) Albacete Spain

5. Laboratorio de Oncología Molecular, Unidad de Medicina Molecular, Centro Regional de Investigaciones Biomédicas, Universidad de Castilla‐La Mancha, Unidad Asociada de Biomedicina UCLM Unidad asociada al CSIC Albacete Spain

6. Departamento de Biología del Cáncer, Instituto de Investigaciones Biomédicas Alberto Sols (CSIC‐UAM), Unidad Asociada de Biomedicina UCLM Unidad asociada al CSIC Madrid Spain

7. Radiation Oncology Department, Gynecological Cancer Unit, ICMHO, Hospital Clinic University of Barcelona, IDIBAPS Barcelona Spain

8. Department of Radiation Oncology Hospital Universitari Sant Joan Reus Spain

Abstract

AbstractPurposeTo compare the clinical outcomes of single‐fraction high‐dose‐rate (HDR) brachytherapy and single‐fraction low‐dose‐rate (LDR) brachytherapy as the sole treatment for primary prostate cancer.Material and MethodsA quasi‐randomized study that allocated, from March 2008 to February 2012, 129 low and intermediate risk prostate cancer patients to one single‐fraction HDR of 19 Gy (61 patients) or to a 145 Gy 125I LDR permanent implant (68 patients. Biochemical relapse‐free survival (bRFS) and overall survival (OS) were compared using the Kaplan–Meier method and Cox regression analysis.ResultsAfter a median follow‐up of 72 months in the HDR group, 26 patients relapsed, and after a median follow‐up of 84 months in the LDR group, 7 patients relapsed (p < 0.0001). The 5‐year bRFS was significantly better for the LDR group than for the HDR group (93.7% and 61.1%, respectively) (p < 0.0001). The 5‐year OS also was significantly better in the LDR group (95.5% vs. 89.9%) (p = 0.0436).ConclusionsPermanent LDR prostate implant brachytherapy offers better clinical outcomes than single‐fraction HDR for prostate cancer.

Publisher

Wiley

Subject

Urology,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/pros.24548

Reference30 articles.

1. Treatment technique evolution and dosimetry trends over seven years of low dose rate prostate brachytherapy at an Australian institution

2. Permanent seed brachytherapy for clinically localized prostate cancer: Long-term outcomes in a 700 patient cohort

3. Progress in Low Dose Rate Brachytherapy for Prostate Cancer

4. Dose Escalation Improves Cancer-Related Events at 10 Years for Intermediate- and High-Risk Prostate Cancer Patients Treated With Hypofractionated High-Dose-Rate Boost and External Beam Radiotherapy

5. Is α/β for prostate tumors really low?